Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA ...

Global Cancer Antibody Drug Conjugates Market Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, Oct. 23, 2024 ...

CAL101 is an anti-S100A4 monoclonal antibody (mAb) and Calluna's lead drug candidate Study demonstrated a favorable safety, pharmacokinetic (PK) and immunogenicity profile CAL101 is ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $266.48 and traded as low as ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

The initial program, dubbed Geneious Luma, aims to focus on monoclonal and multispecific antibodies. It will take the ability ...

Donanemab, the most effective treatment yet for the disease, will be banned on the health service despite regulators ...

In recent months, the Delaware Court of Chancery has decided four significant cases regarding merger agreement earnout provisions. Most notably, ...